Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Liminal BioSciences Reports Second Quarter 2021 Financial Results

PR Newswire August 16, 2021

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

PR Newswire August 9, 2021

Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

PR Newswire July 9, 2021

Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion

Canada NewsWire June 23, 2021

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

Canada NewsWire June 4, 2021

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

Canada NewsWire June 4, 2021

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

Canada NewsWire May 28, 2021

Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

Canada NewsWire May 21, 2021

Liminal BioSciences Reports First Quarter 2021 Financial Results

Canada NewsWire May 17, 2021

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

Canada NewsWire May 17, 2021

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Canada NewsWire March 24, 2021

Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

Canada NewsWire January 27, 2021

Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

Canada NewsWire January 12, 2021

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

Canada NewsWire December 15, 2020

Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at 62nd American Society of Hematology Annual Meeting and Exposition

Canada NewsWire December 7, 2020

Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

Canada NewsWire November 13, 2020

Liminal BioSciences Reports Third Quarter Financial Results

Canada NewsWire November 12, 2020

Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

Canada NewsWire November 10, 2020

Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA

Canada NewsWire November 8, 2020

Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

PR Newswire November 6, 2020